Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference

The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [212Pb]VMT-𝛼-NET for neuroendocrine tumors (NETs)

Funds from the award are directed to Perspective Therapeutics’ collaborator Dr. Samantha Terry PhD, an expert in radiobiology at King’s College London.

  • VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions
  • First melanoma patient screened and imaged with [203Pb]VMT01 to determine eligibility for [212Pb]VMT01 treatment
  • Preliminary results from initial cohorts expected by end of 2023

RICHLAND, WASHINGTON & CORALVILLE, IOWA – June 27, 2023  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s (ABS) annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023.

The presentation entitled Prostate Brachytherapy with Cs-131: Long Term Results Compared to Published SBRT Data, by authors Mohammed A. Mohammed, MD, Ronald M. Benoit, Sushil Beriwal, MD, and Ryan P. Smith, MD was presented by Ryan P. Smith, MD, Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh PA. The authors reported that Cesium-131 prostate brachytherapy provided disease-free survival rates of 97.8% and 96%, at 5 and 10 years respectively.

“We’re excited that a presentation of long-term clinical data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ABS meeting,” said Thijs Spoor, Perspective’s Chief Executive Officer. He added, “The data shows Cesium-131 brachytherapy offers prostate cancer patients the prospect of disease-free survival of 96% ten years after treatment. This coupled with a favorable side effect profile affirms the value of Cesium-131 brachytherapy as a leading option for prostate cancer treatment.”

Commenting on the meeting, Perspective’s EVP of Brachytherapy, Andrew Bright, said, “We were thrilled to be a part of this year’s meeting and to be able to re-emphasize our belief in the clinical value of brachytherapy, and the American Brachytherapy Society’s objectives.” He also remarked “It was an excellent meeting, based on the theme of Delivering the Right Care for Everyone: Advancing Brachytherapy Access for All. Peter Rossi MD, the out-going President of ABS, as well as the entire organization committee should be commended for a very successful meeting.”

Perspective Therapeutics is the world’s only producer of Cesium-131 brachytherapy which is powering expanding internal radiation treatment options throughout the body for prostate cancer as well as difficult to treat lung, brain, gynecological, head and neck, pelvic, and colorectal cancers.

Investor Relations Contact:

LifeSci Advisors
Chuck Padala

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope Lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary Lead-212 generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company’s website at .

Safe Harbor Statement

Statements in this news release about Perspective Therapeutics’ future expectations, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing Perspective Therapeutics, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether additional studies are released that support the conclusions of the studies discussed in this news release, whether ongoing patient results are favorable and in line with the conclusions of clinical studies and initial patient results, physician acceptance, training and use of our products, whether the anticipated benefits of the Company’s therapies are realized; market acceptance and recognition of the Company’s products; the Company’s ability to enforce its intellectual property rights; successful completion of future research and development activities; whether we, our distributors, and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell, and use our products in their various forms; the procedures and regulatory requirements mandated by the FDA for animal trials, human trials, clinical studies, Phase I and II approvals and 510(k) approval and reimbursement codes; changes in applicable laws and regulations applicable to our products, and other risks detailed from time to time in Perspective Therapeutics, Inc., reports filed with the U.S. Securities Exchange Commission.

Scroll to top